Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Disney

Walmart

If you are looking for dividend stocks to buy, you're at the right place; research shows that companies regularly raising payouts, known as “dividend growers,” boast compound annual returns of about 11.7% from 1986 to 2016. Even companies paying dividends but not raising them earned an average of 9.9% per year.

The Dividend Investor's Playbook: 3 Stocks for Consistent Cash Flow in 2024

Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas Collaboration leverages Totus' covalent chemistry-based OmniDEL platform for the identification of small molecule drug candidates across multiple therapeutic areas

Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly

Regeneron Pharmaceuticals

Eli Lilly and Regeneron are developing competing hearing-loss gene therapies. These drugmakers have solid businesses thanks to their innovative qualities.

These 2 No-Brainer Growth Stocks Are Breaking New Ground

Absci Corp

Bristol-Myers

Novo Nordisk

Novartis

Pfizer

Schrodinger 

It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

Eli Lilly said on Thursday that its once-weekly insulin efsitora met the main goals in two late-stage trials evaluating it in people with type 2 diabetes.

Lilly's weekly insulin succeeds in late-stage studies

Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists INDIANAPOLIS , May 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections. In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.

With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin

Amazon

Broadcom

If you think you've missed the rally in high-flying growth stocks, think again. Even though the market is close to all-time highs, many well-known growth stocks still have plenty of room to run.

Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024

Eli Lilly (NYSE: LLY) saw its net income decline by $1 billion or 16% y-o-y to $5.2 billion in 2023. This can primarily be attributed to higher acquired in-process research and development expenses (IPR&D).

How Are Eli Lilly's Profit Margins Trending?

Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.

Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies

Britain's Pharmacy2U said on Wednesday it had cut the prices of weight-loss medication Wegovy and Mounjaro, becoming the latest in a slew of online pharmacies and slimming clinics to do so as initial supply shortages of the drugs ease in the country.

UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down

INDIANAPOLIS , May 15, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer.

Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer

Eli Lilly's top line is expanding quickly for such a large business. Two closely related drugs are to credit for much of the growth.

These 2 Words Explain Why Eli Lilly Stock Is a Buy Right Now

AstraZeneca

STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, today announced that Professor Jan Lundberg has been elected as a new board member at the company's annual general meeting in 2024. Professor Jan Lundberg has more than 25 years of experience from leading positions in global pharmaceutical companies, including as global head of research at Astra and then AstraZeneca (1996 - 2009) and global head of research and development at Eli Lilly (2010 - 2018).

Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member

Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.

Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs

A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.

Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says

Eli Lilly and Novo Nordisk are competing in treating diabetes and obesity. Both have launched successful products in these two markets.

2 Top Pharma Stocks That Just Keep Getting Better and Better

Demand for weight-loss medications such as Ozempic and Mounjaro is soaring. Eli Lilly, the developer of Mounjaro and Zepbound, is investing heavily to meet demand.

Is Eli Lilly's Latest Deal a Gamechanger?

Biotechnology is an interesting place to look if you're looking for growth and are not put off by severe levels of volatility. Undoubtedly, there's a bit of speculative zest regarding some of the smaller biotech stocks out there, many of whom depend on just a handful of pipeline candidates.

Biotech Behemoths: 3 Giants Set to Dominate the Health Scene

AbbVie

Eli Lilly is an ideal stock for growth and dividends. AbbVie is a Dividend King with a bright future.

3 Magnificent Stocks That Are Passive Income Machines

Amgen

Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.

Is Eli Lilly Stock A Better Pick Over Amgen?

Starbucks

Ulta Beauty

High interest rates are here to stay. Federal Reserve Chairman Jerome Powell said the fight against inflation had stalled and the central bank was leaving interest rates unchanged.

The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory

Eli Lilly hit it out of the park once again with its latest financial results. The company has several regulatory catalysts on the horizon.

1 No-Brainer Growth Stock to Buy and Hold

Apple

American Express

Depending on where you look, there has been quite a tough crowd of investors to please this earnings season. Indeed, some companies still managed to blow away the numbers.

Earnings-Proof Tech Plays: 3 Stocks Set to Stay Hot Beyond Reporting Season

Allstate

Microsoft

These S&P 500 stocks are industry leaders with good fundamentals and bullish charts. They may be ones you want to look at as you add exposure.

Five S&P 500 Stocks To Watch In Today's Market; Amazon Stock Hits New High

Arista Networks

Eaton

Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. And that's precisely what these three companies have recently announced.

News for Eli Lilly Stock (LLY)